Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lonsurf + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Taiho Oncology
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
Lonsurf + gemcitabine + nab-paclitaxel is an experimental combination chemotherapy regimen being evaluated for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). The regimen consists of Lonsurf—a fixed-dose oral combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil—administered alongside intravenous gemcitabine and nab-paclitaxel (albumin-bound paclitaxel). Trifluridine exerts its cytotoxic effect by incorporating into viral and cellular DNA, while tipiracil increases trifluridine bioavailability by inhibiting its degradation by thymidine phosphorylase. Gemcitabine further inhibits DNA synthesis by targeting ribonucleoside reductase and incorporating into DNA, and nab-paclitaxel arrests the cell cycle by stabilizing microtubules. This triplet combination is currently being investigated in a Phase I dose-escalation trial sponsored by Patrick Joseph Loehrer Sr. at Indiana University to determine the recommended phase 2 dose (RP2D) for patients with advanced PDAC.
- Other names
- trifluridine + tipiracil + gemcitabine + nab-paclitaxelTAS-102 + gemcitabine + nab-paclitaxel
02
Targets
CDA (Cytidine deaminase)DNA polymerase familyRNR (Ribonucleotide reductase)TYMP (Thymidine phosphorylase)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on Lonsurf + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lonsurf + gemcitabine + nab-paclitaxel.